BMO Global Health Care Fund Advisor Series (BMO99335)
12.73
+0.13
(+1.07%)
CAD |
Dec 19 2025
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 2.07% | 193.88M | 1.05% | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -170.92M | 13.73% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| This fund's objective is to increase the value of your investment over the long term by investing primarily in companies that operate in, or are expected to benefit from, health care related businesses from around the world. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health Care Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | BMO Global Asset Management |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
34
-7.709M
Peer Group Low
23.99M
Peer Group High
1 Year
% Rank:
89
-170.92M
-350.65M
Peer Group Low
307.01M
Peer Group High
3 Months
% Rank:
99
-186.09M
Peer Group Low
39.43M
Peer Group High
3 Years
% Rank:
26
-801.27M
Peer Group Low
605.94M
Peer Group High
6 Months
% Rank:
99
-181.73M
Peer Group Low
177.46M
Peer Group High
5 Years
% Rank:
25
-463.78M
Peer Group Low
1.323B
Peer Group High
YTD
% Rank:
89
-319.55M
Peer Group Low
285.10M
Peer Group High
10 Years
% Rank:
31
-299.21M
Peer Group Low
1.550B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 22, 2025.
Asset Allocation
As of November 30, 2025.
| Type | % Net |
|---|---|
| Cash | 0.85% |
| Stock | 99.14% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 11.88% | 1076.32 | 0.46% |
| AstraZeneca PLC | 6.61% | 180.75 | -0.26% |
| Johnson & Johnson | 6.48% | 207.26 | 0.43% |
| AbbVie, Inc. | 6.41% | 227.82 | 0.44% |
| UCB SA | 5.11% | 275.02 | -2.56% |
| Cogent Biosciences, Inc. | 4.18% | 39.35 | -0.51% |
| Abbott Laboratories | 3.84% | 125.21 | -0.19% |
| Boston Scientific Corp. | 3.71% | 96.42 | 0.85% |
| McKesson Corp. | 3.61% | 818.23 | -0.25% |
| UnitedHealth Group, Inc. | 3.55% | 325.17 | -0.69% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP |
|
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 500.00 None |
| Minimum Subsequent Investment | 50.00 None |
Basic Info
| Investment Strategy | |
| This fund's objective is to increase the value of your investment over the long term by investing primarily in companies that operate in, or are expected to benefit from, health care related businesses from around the world. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health Care Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | BMO Global Asset Management |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (12-19-25) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 10 |
| Stock | |
| Weighted Average PE Ratio | 38.00 |
| Weighted Average Price to Sales Ratio | 7.679 |
| Weighted Average Price to Book Ratio | 10.43 |
| Weighted Median ROE | 197.7% |
| Weighted Median ROA | 5.91% |
| ROI (TTM) | 9.81% |
| Return on Investment (TTM) | 9.81% |
| Earning Yield | 0.0332 |
| LT Debt / Shareholders Equity | 2.926 |
| Number of Equity Holdings | 10 |
As of November 30, 2025
Growth Metrics
| EPS Growth (1Y) | 30.99% |
| EPS Growth (3Y) | 10.97% |
| EPS Growth (5Y) | 11.54% |
| Sales Growth (1Y) | 14.86% |
| Sales Growth (3Y) | 9.38% |
| Sales Growth (5Y) | 12.84% |
| Sales per Share Growth (1Y) | 14.13% |
| Sales per Share Growth (3Y) | 9.75% |
| Operating Cash Flow - Growth Rate (3Y) | 3.53% |
As of November 30, 2025
Fund Details
| Key Dates | |
| Inception Date | -- |
| Last Annual Report Date | 9/30/2024 |
| Last Prospectus Date | -- |
| Share Classes | |
| BMO70335 | Commission-based Advice |
| BMO71335 | Institutional |
| BMO95335 | Fee-based Advice |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | No |
| Leveraged Fund | -- |
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Synthetic Replication Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:BMO99335.TO", "name") |
| Broad Asset Class: =YCI("M:BMO99335.TO", "broad_asset_class") |
| Broad Category: =YCI("M:BMO99335.TO", "broad_category_group") |
| Prospectus Objective: =YCI("M:BMO99335.TO", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |